In this sense, targeting Syk has been previously explored using fostamatinib, [11, 10, 12, 30] although some activity was reported in a phase 2 study in NHL and CLL, [13] further clinical development in B-cell malignancies has not been reported. Here, SYK is linked to non-Hodgkin lymphoma.